clinical trial · NCT07392970
Motixafortide for MRD Sensitization in AML
Acute Myeloid LeukemiaMeasurable Residual DiseaseMotixafortide
brief summary
This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid leukemia (AML) who have completed induction treatment. Consenting and eligible patients will undergo standard of care (SOC) bone marrow and peripheral blood assessments with SOC MRD assays, followed by a single injection of motixafortide. Ten to 14 hours after injection, the patient will undergo peripheral blood collection for the same applicable MRD tests
started
Jul 23, 2026
primary completion
Aug 2, 2028
completion
Feb 2, 2030
last updated
Jul 24, 2026
official title
A Pilot Clinical Trial of Motixafortide for Measurable Residual Disease (MRD) Sensitization in Acute Myeloid Leukemia (AML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol